01—Abstract
Summary
Summary of the 8-K filed September 10, 2026. Cited figures are marked; the original filing is the authoritative source.
On September 10, 2026, Labcorp Holdings Inc. (NYSE: LH) hosted its 2026 Investor Day, providing an in-depth review of its growth strategy, innovation roadmap, and long-term financial outlook.
The company reaffirmed its full-year 2026 guidance, which was last updated on July 30, 2026, calling for Labcorp Enterprise revenue of $14.71 billion to $14.83 billiona, adjusted EPS of $18.10 to $18.55, and free cash flow of $1.24 billion to $1.36 billion. For the longer term, Labcorp outlined expectations through 2029 of compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by the end of 2029, compound annual adjusted EPS growth of 8.5% to 11.5%, and free cash flow growth in line with adjusted earnings growth. Management described four strategic priorities: specialty testing (oncology, neurology, autoimmune diseases and women's health), partnerships with health systems and pharmaceutical companies, personalized health solutions, and technology including AI and robotics.
The outlook assumes foreign exchange rates as of June 30, 2026 and incorporates potential return of PAMA. The Investor Day materials, furnished as Exhibits 99.1 and 99.2, also present a capital deployment framework for 2027 to 2029 that includes operating cash flow of $6.3 billion to $7.2 billionb, capital expenditures of approximately 4% of revenue, dividends targeted at 15% to 20% of adjusted earnings, and M&A contributing 1.5% to 2.5% revenue CAGR. The information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Reaffirmed 2026 guidance: Labcorp Enterprise revenue of $14,710 million to $14,827 million (growth of 5.4% to 6.3%), adjusted EPS of $18.10 to $18.55, and free cash flow of $1,240 million to $1,360 million.
- Long-term outlook through 2029 calls for 5% to 8% compound annual revenue growth and 8.5% to 11.5% compound annual adjusted EPS growth.
- Adjusted operating margin expansion of 75 to 150 basis points expected by the end of 2029.
- Four strategic priorities: specialty testing (oncology, neurology, autoimmune, women's health), health system and pharma partnerships, personalized health solutions, and AI and robotics technology.
- Organic revenue growth expected at 3.5% to 5.5% CAGR, with acquisition revenue contributing 1.5% to 2.5% CAGR through 2029.
- Planned 2027 to 2029 operating cash flow of $6.3 billion to $7.2 billion, with capital expenditures around 4% of revenue and dividends targeted at 15% to 20% of adjusted earnings.
- LaunchPad productivity savings of $125 million to $150 million per year are assumed in the margin outlook.
03—Questions
Frequently Asked Questions
Did Labcorp change its 2026 guidance at Investor Day?
No. Labcorp reaffirmed its full-year 2026 guidance, which was last updated on July 30, 2026, and assumes foreign exchange rates effective as of June 30, 2026.
What long-term financial targets did Labcorp provide?
Labcorp expects compound annual revenue growth of 5% to 8% and compound annual adjusted EPS growth of 8.5% to 11.5% through 2029, along with adjusted operating margin expansion of 75 to 150 basis points by the end of 2029 and free cash flow growth in line with adjusted earnings growth.
What assumptions underlie the 2029 outlook?
The outlook assumes foreign exchange rates as of June 30, 2026, potential return of PAMA, financial leverage of 2.5x to 3.0x gross debt to TTM adjusted EBITDA, an adjusted effective tax rate of approximately 23%, and LaunchPad savings of $125 million to $150 million per year, and includes the estimated impact of anticipated capital deployment.
How does Labcorp plan to deploy capital?
For 2027 to 2029, the illustrative plan includes $6.3 billion to $7.2 billion of operating cash flow, capital expenditures of about 4% of revenue, M&A driving 1.5% to 2.5% revenue CAGR, dividends targeted at 15% to 20% of adjusted earnings, and share repurchases used at minimum to cover share dilution.
Are the Investor Day materials considered filed with the SEC?
No. The filing states that the information, including the exhibits, is furnished under Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.
04—Continue